Aspira Womens Health, Inc. (Nasdaq: AWH) 28% HIGHER; entered into an agreement with Dana-Farber Cancer Institute (DFCI), Brigham and Womens Hospital, and Medical University Lodz to evaluate their novel microRNA (miRNA) technology in combination with current AWH technologies, for the development of a highly sensitive and specific high-risk early detection test for ovarian cancer. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender-specific cancer with an over 50 percent mortality rate impacting women of all ages and... More
Science Applications Int'l (NYSE: SAIC) reported Q4 EPS of $1.67, $0.22 better than the analyst estimate of $1.45. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.78 billion.
Science Applications Int'l sees FY2022 EPS of $6.00-$6.25, versus the... More